Access to the New Deal shows that Chinese medicine exports to the EU have plummeted by 50%

The implementation of the new EU traditional herbal medicine policy implemented on April 30 this year has begun to show its impact on Chinese medicine exports. Yesterday, the reporter learned from the Medical Insurance Association that in June China's exports of Chinese patent medicine products had dropped to half of the same period last year. China's Chinese medicine companies finally paid a price for their preparation for the seven-year preparation period before the implementation of the New Deal.

The Medical Insurance Association announced in its latest “Analysis on the Import and Export Situation of Pharmaceuticals in the First Half of 2011 and the Outlook for the Second Half of 2011” that on April 30 this year, the EU set the Herbal Medicine Directive in the EU's Traditional Herbal Drugs Directive for 2004 for 7 years. Due to the expiration of the transition period of sales, China has not registered a successful Chinese patent medicine in 7 years, so the export of Chinese proprietary Chinese medicine products to the EU has been greatly affected. Exports have dropped to 50% in the same period of last year as of June.

The EU has always been the largest vegetable drug market in the world, with annual sales of 10 billion euros, accounting for more than 40% of the world's plant drug market share. If you abandon this market, it will be a huge loss to Chinese medicine companies.

Liu Zhanglin, deputy director of the China Medicare Association, told reporters that the implementation of the EU's New Deal still has a certain course. Now that the United Kingdom has announced the suspension of imports of Chinese medicines, although some countries in Northern Europe have no mandatory regulations, their distributors are already worried about their future market prospects. Stop imports, which has brought shocks to the export of Chinese medicine. "Next, as the new policy for Chinese medicine is widely implemented in the European Union, exports of Chinese medicine companies will also face greater difficulties." A person in charge of a Chinese medicine company that does not wish to be named predicts.

However, Liu Zhanglin also pointed out that the good news is that many Chinese medicine companies now see the importance of the EU market. Lanzhou Foci Pharmaceutical Company has formally submitted applications for the registration of Chinese medicine products to the Swedish National Drug Administration, and there are at least 78 companies to prepare. Submit an application for registration of Chinese medicine to the EU. At the same time, due to the mutual recognition of the drug law among EU member states, if one can apply for a successful registration in one country, it means that it will be able to obtain an “admittance permit” for sales in the EU’s pharmaceutical mainstream market.